Eurotium cristatum product and applications thereof

A technology of coronoid spores and spores of spores, applied to medical preparations containing active ingredients, plant/algae/fungus/moss components, plant raw materials, etc., which can solve adverse side effects, single effect, and ineffective curative effect Good and other questions

Pending Publication Date: 2020-10-23
XIAN GIANT BIOGENE TECH CO LTD
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The existing therapeutic drugs have a single effect and often require the combined use of multiple drugs to treat, but the quality is difficult to control, the risk of drug use is high, and it is more likely to cause symptoms such as cerebral hemorrhage
However, high-efficiency drugs are accompanied by adverse toxic and side effects, and there are safety risks; drugs that guarantee safety have disadvantages such as poor curative effect and slow effect.
In addition, due to the complexity and particularity of the disease, the course of treatment is long and the time is long, so its application in the market has certain limitations.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Eurotium cristatum product and applications thereof
  • Eurotium cristatum product and applications thereof
  • Eurotium cristatum product and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] The preparation of the hyphae and spore of embodiment 1 coronoid saccharomyces

[0032] The taxonomy of the coronoid used in this embodiment is named Eurotium cristatum, which was preserved in the General Microorganism Center of China Microbiological Culture Collection Management Committee on April 2, 2018, and the preservation number is CGMCC NO.15398. It is also from the Isolated from Fu tea.

[0033] (1) Preparation of Mycelia of Mycelia coronoidis

[0034] According to the inoculum amount of 8%-10%, inoculate P. coronoidis in the fermenter containing 10L zinc-rich liquid submerged fermentation medium, wherein, the medium is: glucose 25g / L, peptone 2g / L by mass volume ratio , corn steep liquor dry powder 2.5g / L, yeast powder 10g / L, KH 2 PO 4 2g / L, MgSO 4 7H2O 4.1g / L, (NH4) 2 SO4 5g / L, sodium zincite 33.3mg / L, culture temperature 28-30℃, pH 5.0-5.5, air flow 5-20L / min, culture for 96h, collect the hyphae in the fermentation product, put it in Dry at 60-65°C for...

Embodiment 2

[0039] Preparation of Example 2 Coronoid Saccharomyces coronoidis product-capsule

[0040] The mycelia and spores of the Mycelia coronoidis prepared in Example 1 were used to prepare the capsule form of the Mycocystis coronoidis product according to different ratios. Specifically, the following 5 different capsules were prepared according to different proportions.

[0041] (1) Make capsules according to the ratio in Table 1 (1000 capsules, the content of S. coronoidis 200mg / capsule).

[0042] Table 1 The composition ratio of Coronary cyst capsules

[0043]

[0044](2) Capsules (1000 capsules, 200 mg / capsule of S. coronoidis content) were made according to the proportioning in Table 2.

[0045] Table 2 The composition ratio of Coronary cyst powder capsules

[0046]

[0047] (3) Make capsules according to the proportioning in Table 3 (1000 capsules, the content of S. coronoidis 200 mg / capsule).

[0048] Table 3 The composition ratio of Coronary cyst capsules

[0049] ...

Embodiment 3

[0058] Preparation of Example 3 Coronoid Saccharomyces coronaris products-tablet

[0059] According to the proportioning of Table 6, tablet (1000 tablets, 200mg / tablet of S. coronoidis content) is made.

[0060] Table 6 The component distribution ratio of Cystis coronaris

[0061]

[0062] Specifically, during preparation, pass the above-mentioned main ingredients and auxiliary materials through 80-mesh sieves, mix well, use 75% ethanol as a binder, granulate with 16-mesh sieves, dry at 55-60 ° C, and granulate with 14-mesh sieves. Granules, compressed tablets, 0.3g per tablet.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a eurotium cristatum product. The eurotium cristatum product comprises ceurotium cristatum and pharmaceutically acceptable auxiliary materials. The invention also provides an application of the eurotium cristatum product to preparation of drugs for preventing and treating cerebral thrombosis and applications of the eurotium cristatum product to reduction of total cholesterolcontent, triglyceride content and malondialdehyde content in blood, blood viscosity and cerebrovascular permeability, or improvement of superoxide dismutase activity. The eurotium cristatum product can inhibit formation of thrombus, reduce the content of total cholesterol and triglyceride in blood, blood viscosity, cerebrovascular permeability and malondialdehyde level, and improve superoxide dismutase activity, and has certain prevention or treatment effect on cerebral thrombosis. Compared with the prior art, the product has the advantages of no toxic or side effect, quick effect and good curative effect, provides a novel curative idea for cerebral thrombosis disease and has wide application prospect.

Description

technical field [0001] The invention belongs to the technical field of biological bacterial agents, and in particular relates to a product and an application of a coronoid saccharomyces coronoidis. Background technique [0002] Cerebral thrombosis, as a serious ischemic cerebrovascular disease, is one of the three major killers of human death and poses a fatal threat to human health. According to epidemiological data, the incidence of cerebral thrombosis accounts for more than 80% of the total number of cerebrovascular diseases. In the past century, the morbidity and mortality of cerebral thrombosis in the whole country have been showing an increasing trend. Cerebral thrombosis is a common brain disease, mainly due to cerebral artery trunk or cortical branch atherosclerosis leads to thickening of the vessel wall, narrowing of the lumen, occlusion, or formation of thrombus on this basis, causing local blood flow in the brain Reduced, interrupted blood supply, brain tissue i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/062A61P7/02A61P3/06
CPCA61K36/062A61P3/06A61P7/02
Inventor 范代娣董杨芳段志广宇文伟刚严建亚
Owner XIAN GIANT BIOGENE TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap